Literature DB >> 12716217

Guidelines for the management of acne vulgaris in adolescents.

Victoria Goulden1.   

Abstract

This article reviews the treatment of acne in adolescents. The choice of therapy should be principally based on the type of lesion and the severity of the acne, but psychosocial disability relating to the disease and the presence of scarring may also influence the approach to treatment.Mild acne generally requires topical treatment only. Benzoyl peroxide, azelaic acid, and antibacterials are generally used for inflammatory lesions. Topical retinoids are particularly effective for noninflamed lesions, and combination therapies are useful for mixed lesions. Moderately severe acne generally requires oral antibacterials. Tetracyclines/oxytetracycline and erythromycin are usually the first-line antibacterials. Second-generation tetracyclines, such as lymecycline, doxycycline, and minocycline, show improved absorption. Minocycline has the advantage of being rarely associated with Propionibacterium acnes antibacterial resistance, but can occasionally lead to potentially serious adverse effects. Trimethoprim is a useful third-line antibacterial therapy for patients resistant to other antibacterial therapies. Benzoyl peroxide should generally be used in combination with oral antibacterials as this has been shown to reduce the development of antibacterial resistance. For severe nodular acne, isotretinoin is the treatment of choice. In addition, over recent years dermatologists have increasingly used this drug to treat patients with moderate acne which has not responded to other systemic therapies, particularly when associated with scarring or significant psychological disability. However, this use is outside the current license of the drug. Isotretinoin is associated with a number of serious adverse effects and careful monitoring of patients during therapy is required.Physical therapies for the treatment of acne nodules and macrocomedones are also important adjuncts to drug therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12716217     DOI: 10.2165/00128072-200305050-00003

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  73 in total

1.  A comparison of doxycycline and minocycline in the treatment of acne vulgaris.

Authors:  P V Harrison
Journal:  Clin Exp Dermatol       Date:  1988-07       Impact factor: 3.470

2.  Phototoxic eruptions due to doxycycline--a dose-related phenomenon.

Authors:  A M Layton; W J Cunliffe
Journal:  Clin Exp Dermatol       Date:  1993-09       Impact factor: 3.470

3.  Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

Authors:  A Y Finlay; G K Khan
Journal:  Clin Exp Dermatol       Date:  1994-05       Impact factor: 3.470

4.  Acne vulgaris--its aetiology and treatment. A review.

Authors:  W J Cunliffe; A D Clayden; D Gould; N B Simpson
Journal:  Clin Exp Dermatol       Date:  1981-09       Impact factor: 3.470

Review 5.  [Minocycline].

Authors:  C Bernier; B Dréno
Journal:  Ann Dermatol Venereol       Date:  2001-05       Impact factor: 0.777

Review 6.  Uses and complications of isotretinoin therapy.

Authors:  C N Ellis; K J Krach
Journal:  J Am Acad Dermatol       Date:  2001-11       Impact factor: 11.527

7.  Practical use of a disability index in the routine management of acne.

Authors:  R J Motley; A Y Finlay
Journal:  Clin Exp Dermatol       Date:  1992-01       Impact factor: 3.470

8.  Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment.

Authors:  A M Layton; H Knaggs; J Taylor; W J Cunliffe
Journal:  Br J Dermatol       Date:  1993-09       Impact factor: 9.302

9.  Effects of vitamin A acid in skin: in vivo and in vitro studies.

Authors:  E Christophers; H H Wolff
Journal:  Acta Derm Venereol Suppl (Stockh)       Date:  1975 Jan 27-29

10.  Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure.

Authors:  E A Eady; J H Cove; K T Holland; W J Cunliffe
Journal:  Br J Dermatol       Date:  1989-07       Impact factor: 9.302

View more
  8 in total

1.  Effective monitoring of isotretinoin safety in a pediatric dermatology population: a novel "patient symptom survey" approach.

Authors:  Chelsea J Hodgkiss-Harlow; Lawrence F Eichenfield; Magdalene A Dohil
Journal:  J Am Acad Dermatol       Date:  2011-05-31       Impact factor: 11.527

Review 2.  A Comprehensive Critique and Review of Published Measures of Acne Severity.

Authors:  Tamara Agnew; Gareth Furber; Matthew Leach; Leonie Segal
Journal:  J Clin Aesthet Dermatol       Date:  2016-07-01

3.  Clindamycin Phosphate 1.2% and Benzoyl Peroxide 2.5% Gel for the Treatment of Moderate-to-severe Acne: An Update.

Authors:  Michael H Gold
Journal:  J Clin Aesthet Dermatol       Date:  2012-01

Review 4.  Use of minocycline in viral infections.

Authors:  Kallol Dutta; Anirban Basu
Journal:  Indian J Med Res       Date:  2011-05       Impact factor: 2.375

Review 5.  Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments.

Authors:  Martin Steinhoff; Marc Vocanson; Johannes J Voegel; Feriel Hacini-Rachinel; Gregor Schäfer
Journal:  Adv Ther       Date:  2016-07-18       Impact factor: 3.845

6.  Non-antibiotic Isotretinoin Treatment Differentially Controls Propionibacterium acnes on Skin of Acne Patients.

Authors:  Angela E Ryan-Kewley; David R Williams; Neill Hepburn; Ronald A Dixon
Journal:  Front Microbiol       Date:  2017-07-25       Impact factor: 5.640

Review 7.  Tetracycline and viruses: a possible treatment for COVID-19?

Authors:  Jesús A Mosquera-Sulbaran; Hugo Hernández-Fonseca
Journal:  Arch Virol       Date:  2020-11-02       Impact factor: 2.574

8.  Adherence to drug treatments and adjuvant barrier repair therapies are key factors for clinical improvement in mild to moderate acne: the ACTUO observational prospective multicenter cohort trial in 643 patients.

Authors:  Raúl de Lucas; Gerardo Moreno-Arias; Montserrat Perez-López; Ángel Vera-Casaño; Sonia Aladren; Massimo Milani
Journal:  BMC Dermatol       Date:  2015-09-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.